RECRUITING

UPBEAT: Using Polygenic Scores to Guide BB Therapy in HF With Mildly Reduced EF

Description

This study will use polygenic scores, a tool which describes differences in genetics, to examine effectiveness of beta blocker medication in heart failure patients with ejection fraction of 41-50 percent. The study will also assess beta blockers' effect on the changes in left ventricular end-systolic volume index by MRI.

Conditions

Heart FailurePolygenic Score
Talk to us

Related Conditions:

Heart FailurePolygenic Score

Study Overview

On this page

Study Details

Study overview

This study will use polygenic scores, a tool which describes differences in genetics, to examine effectiveness of beta blocker medication in heart failure patients with ejection fraction of 41-50 percent. The study will also assess beta blockers' effect on the changes in left ventricular end-systolic volume index by MRI.

Using Polygenic Scores to Guide Beta-blocker Therapy for Heart Failure With Mildly Reduced Ejection Fraction

UPBEAT: Using Polygenic Scores to Guide BB Therapy in HF With Mildly Reduced EF

Condition
Heart Failure
Intervention / Treatment

-

Contacts and Locations

Detroit

Henry Ford Health, Detroit, Michigan, United States, 48202

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Age 18-89 years
  • * Ejection Fraction (EF) \>40% and =\<50% by any modality within 1 year (must be most recent)
  • * Clinical diagnosis of HF within 1 year, evidenced by any one: Hospital discharge with primary or secondary HF diagnosis, ER discharge with primary diagnosis of HF, ambulatory diagnostic code for HF and diuretic use, BNP\>35 ng/L or NTproBNP \>125 ng/L at any time
  • * Unable to provide informed consent
  • * Previous documented EF =\< 35%
  • * Currently on BB \>25% target dose
  • * Uncontrolled hypertension (systolic BP \> 180 at enrollment)
  • * Has contraindications to all BB or intolerance to metoprolol
  • * Systolic BP \< 100 or heart rate \<70
  • * Current cancer requiring active treatment
  • * Heart transplant or LVAD or expected in the next year
  • * Life expectancy \< 1 year for any reason
  • * Dialysis dependence or ESRD
  • * MI/ PCI/ CABG within 90 days prior to enrollment or planned in the future
  • * Absolute indication for BB other than heart failure (e.g. tachyarrhythmia required BB for rate control, angina)
  • * If PI decides for any reason participation in trial is not in best interest of the patient

Ages Eligible for Study

18 Years to 89 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

David Lanfear,

David Lanfear, MD, PRINCIPAL_INVESTIGATOR, Henry Ford Health

Study Record Dates

2026-08